Non-Cystic Fibrosis Bronchiectasis Market Report 2026

Non-Cystic Fibrosis Bronchiectasis Market Overview

• Non-Cystic Fibrosis Bronchiectasis market size has reached to $3.7 billion in 2025 • Expected to grow to $4.92 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Non-Cystic Fibrosis Bronchiectasis Market Thrives On Surging Respiratory Disease Cases • Market Trend: Innovations In Targeted Anti-Inflammatory Therapies Enhance Protease Regulation And Airway Remodeling Control In Non-Cystic Fibrosis Bronchiectasis • North America was the largest region in 2025.

What Is Covered Under Non-Cystic Fibrosis Bronchiectasis Market?

Non-cystic fibrosis bronchiectasis is a chronic condition characterized by permanent and abnormal widening of the airways (bronchi) in the lungs. This results from repeated inflammation and infection, leading to damage and weakening of the bronchial walls. It can cause mucus buildup, persistent coughing, breathlessness, and recurrent respiratory infections. Treatment often involves managing symptoms, preventing exacerbations, and addressing underlying causes such as bacterial infections or immune system dysfunction. The main diagnosis types of non-cystic fibrosis bronchiectasis include computed tomography (CT) scans, bronchoscopies, chest X-rays, lung function, sputum culture tests, blood tests, and others. A CT scan provides detailed images of the lungs, helping to diagnose bronchiectasis by revealing the extent and location of lung damage. The treatment types are categorized into surgery, physiotherapy, vaccination, airway pharmacotherapy, antibiotics, and others, and their end uses include hospitals and clinics, ambulatory care centers, and others.

What Is The Non-Cystic Fibrosis Bronchiectasis Market Growth Forecast?

The non-cystic fibrosis bronchiectasis market size is expected to see strong growth in the next few years. It will grow to $4.92 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising prevalence of chronic respiratory diseases, increasing adoption of ai and precision medicine, growth in home healthcare and telemedicine, advancements in minimally invasive treatments, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include rising adoption of personalized treatment approaches, increasing implementation of remote patient monitoring & telehealth, growing use of ai-powered diagnostic tools, expanding deployment of connected health devices & smart lungs monitoring, advancing integration of data-driven clinical decision support.

Global Non-Cystic Fibrosis Bronchiectasis Market Segmentation

1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types 2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments 3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses Subsegments: 1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT 2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy 3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray 4) By Lung Function: Spirometry, Peak Flow Measurement 5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture 6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels 7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test

What Is The Driver Of The Non-Cystic Fibrosis Bronchiectasis Market?

The rising prevalence of respiratory diseases is expected to propel the growth of the non-cystic fibrosis bronchiectasis market going forward. Respiratory diseases encompass a range of conditions affecting the lungs and respiratory system, impacting breathing and overall respiratory function. The rising prevalence of respiratory diseases is primarily driven by increasing environmental pollution, including both outdoor pollutants and indoor irritants such as tobacco smoke. The increasing prevalence of respiratory infections presents opportunities for advancing understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health efforts. For instance, in June 2023, according to a report published by the Office for Health Improvement and Disparities, a UK-based governmental body, a total of 4,622 notifications of scarlet fever Group A Streptococcus bacteria were received from week 37 to week 46 during the 2022-2023 season in England, with 851 notifications received in week 46 alone. This is significantly higher compared to an average of 1,294 notifications (ranging from 258 to 2,008) for the same period (weeks 37 to 46) over the previous five years. Therefore, the rising prevalence of respiratory diseases will drive the growth of the non-cystic fibrosis bronchiectasis industry.

Key Players In The Global Non-Cystic Fibrosis Bronchiectasis Market

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc., Insmed Incorporated, Armata Pharmaceuticals Inc., Renovion Inc., SolAeroMed Inc., CSL Behring, Haisco Pharmaceutical Group Co Ltd., NovaBiotics Ltd., Synspira Therapeutics, Parion Sciences, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Infex Therapeutics

Global Non-Cystic Fibrosis Bronchiectasis Market Trends and Insights

Major companies operating in the non-cystic fibrosis bronchiectasis (NCFB) market are focusing on developing advanced solutions, such as novel neutrophil elastase–regulating pharmacologic interventions, to improve protease–antiprotease balance, mitigate chronic tissue damage, and support sustained control of airway remodeling. Novel neutrophil elastase–regulating pharmacologic intervention for chronic airway inflammation refers to a targeted therapeutic strategy designed to modulate excessive neutrophil elastase activity, an underlying driver of airway injury and persistent inflammation in NCFB. For instance, in November 2025, Insmed, a US-based biopharmaceutical company, received European Commission approval for BRINSUPRI (brensocatib), a first-in-class, once-daily oral DPP1 inhibitor. The 25 mg formulation demonstrated in the Phase 3 ASPEN trial a 19.4% reduction in annual exacerbation rate compared to placebo, prolonged time to first exacerbation, and a greater proportion of patients remaining exacerbation-free. Additionally, it significantly attenuated the decline in lung function (FEV₁) at week 52 and showed a favorable safety profile, with commonly reported adverse effects including headache, hyperkeratosis, dermatitis, rash, upper respiratory tract infections, and dry skin.

What Are Latest Mergers And Acquisitions In The Non-Cystic Fibrosis Bronchiectasis Market?

In November 2023, Chiesi Farmaceutici SpA, an Italy-based pharmaceutical company, partnered with Haisco Pharmaceutical Group Co., Ltd. Through this partnership, Haisco will commercialize Chiesi's investigational bronchiectasis drug in China. This collaboration involves Haisco's financial and logistical support to facilitate the regulatory approval, marketing, and distribution efforts necessary for introducing the bronchiectasis drug to the Chinese market. Haisco Pharmaceutical Group Co. Ltd. is a China-based pharmaceutical company involved in the development of respiratory disease treatments such as bronchiectasis.

Regional Outlook

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Cystic Fibrosis Bronchiectasis Market?

The non-cystic fibrosis bronchiectasis market consists of revenues earned by entities by providing services such as diagnostic imaging, pulmonary function testing, medical consultations, home healthcare, pulmonary rehabilitation, and management of chronic respiratory infections through pharmaceutical treatments and advanced therapeutic technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-cystic fibrosis bronchiectasis market also includes sales of antibiotics, bronchodilators, mucolytics, inhalers, nebulizers, airway clearance devices, and respiratory monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Cystic Fibrosis Bronchiectasis Market Report 2026?

The non-cystic fibrosis bronchiectasis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-cystic fibrosis bronchiectasis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.